BIOMERICA INC (BMRA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Aug 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BMRA SEC filings page.
BIOMERICA INC (BMRA) reported $4.5M in revenue for fiscal year 2026, down 16.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Biomerica’s reported business remains too small to absorb its operating base, with recurring losses funded increasingly through financing rather than operations.
Revenue fell16.0% in FY2026 while SG&A rose to$4.9M , showing overhead did not contract with sales. Gross profit was only$362K against that operating expense, so margin pressure and fixed costs combined to keep the business deeply unprofitable.
The cash picture follows the income statement: FY2026 operating cash flow was
The current ratio fell from 2.8x to 1.6x, leaving less short-term asset coverage for each dollar of current obligations. Debt-to-equity reached 1.6x, while reported liquidity equaled 4.6 months of the latest annual operating outflow, linking weaker balance-sheet flexibility with continued cash needs.
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BIOMERICA INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BIOMERICA INC held $1.3M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $3.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and BIOMERICA INC scores 17/100 among other emerging companies.
BIOMERICA INC had 5M shares outstanding at the end of fiscal year 2026, against 3M in fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and BIOMERICA INC scores 85/100 among other emerging companies.
BIOMERICA INC spent $788K on research and development in fiscal year 2026, which was 8.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and BIOMERICA INC scores 31/100 among other emerging companies.
BIOMERICA INC reported revenue of $4.5M in fiscal year 2026, against $5.3M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and BIOMERICA INC scores 32/100 among other emerging companies.
BIOMERICA INC's operations used $3.4M of cash in fiscal year 2026, against $3.8M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and BIOMERICA INC scores 64/100 among other emerging companies.
BIOMERICA INC's cash, cash equivalents and investments came to $1.3M at the end of fiscal year 2026, against $4.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and BIOMERICA INC scores 34/100 among other emerging companies.
BIOMERICA INC scores -12.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.4M) relative to total liabilities ($4.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BIOMERICA INC passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
BIOMERICA INC reported a net loss of $3.8M while operations used $3.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
BIOMERICA INC generated $876K in revenue in Q4 2026. This represents an increase of 17.0% from the same quarter a year earlier. Against the prior quarter it is down 11.2%.
BIOMERICA INC's EBITDA was -$1.5M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.9% from the same quarter a year earlier. Against the prior quarter it is down 18.5%.
BIOMERICA INC reported -$1.1M in net income in Q4 2026. This represents an increase of 25.8% from the same quarter a year earlier. Against the prior quarter it is up 12.7%.
BIOMERICA INC earned -$0.38 per diluted share (EPS) in Q4 2026. Against the prior quarter it is up 13.6%.
Cash & Balance Sheet
BIOMERICA INC held $1.3M in cash as of Q4 2026; long-term debt is not reported for that period.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
BIOMERICA INC's gross margin was -7.9% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 25.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.4 percentage points.
BIOMERICA INC's ROE was -43.5% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.0 percentage points.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BIOMERICA INC invested $205K in research and development in Q4 2026. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is up 15.2%.
Not reported for Q4 2026.
Not reported for Q4 2026.
BMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $876K+17.0% | $987K-11.8% | $1.2M-26.0% | $1.4M-23.6% | $749K-33.0% | $1.1M+10.0% | $1.6M+4.4% | $1.8M+5.5% |
| Cost of Revenue | $945K-5.1% | $1.0M-6.3% | $1.2M-3.3% | $956K-37.0% | $996K-9.0% | $1.1M-5.7% | $1.2M-3.5% | $1.5M+16.7% |
| Gross Profit | -$69K+72.1% | -$44K-331.6% | $51K-88.3% | $424K+46.7% | -$247K-1173.9% | $19K+112.8% | $437K+34.5% | $289K-29.9% |
| R&D Expenses | $205K-18.7% | $178K-18.0% | $193K-24.9% | $212K-28.6% | $252K-4.5% | $217K-36.7% | $257K-37.6% | $297K-37.1% |
| SG&A Expenses | $1.3M+17.8% | $1.1M+6.3% | $1.2M+4.9% | $1.3M-2.2% | $1.1M-17.0% | $1.0M-32.9% | $1.2M-22.9% | $1.4M+16.0% |
| Operating Income | -$1.5M+2.2% | -$1.3M-7.3% | -$1.4M-38.3% | -$1.1M+18.3% | -$1.6M-2.6% | -$1.2M+39.5% | -$993K+38.2% | -$1.4M-11.0% |
| EBITDA | -$1.5M+1.9% | -$1.3M-7.5% | -$1.4M-39.3% | -$1.1M+18.5% | -$1.5M | -$1.2M+39.9% | -$971K | -$1.3M-11.2% |
| Income Tax | $7K+75.0% | $8K+300.0% | $5K+266.7% | $3K-25.0% | $4K-42.9% | -$4K-200.0% | -$3K-137.5% | $4K-82.6% |
| Net Income | -$1.1M+25.8% | -$1.3M-12.8% | -$1.3M-38.9% | $2K+100.2% | -$1.5M-8.7% | -$1.2M+39.4% | -$950K+37.0% | -$1.3M-16.3% |
| EPS (Basic) | -$0.38+80.8% | -$0.44+8.3% | -$0.45-650.0% | $0.00+100.0% | -$1.98+23.0% | -$0.48-336.4% | -$0.06+33.3% | -$0.63-800.0% |
| EPS (Diluted) | -$0.38 | -$0.44 | -$0.45 | $0.00 | -$1.98 | -$0.48 | -$0.06+33.3% | -$0.63 |
| Diluted Shares (Avg) | N/A | 3M | 3M | 3M | N/A | 2M | 2M-87.3% | 2M |
Not reported in any period shown, so not listed: Interest Expense.
BMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.8M+13.7% | $4.9M-33.9% | $6.0M-17.0% | $6.9M-12.9% | $5.9M-35.8% | $7.4M-28.7% | $7.3M-38.5% | $7.9M-40.5% |
| Current Assets | $4.0M-17.6% | $4.1M-33.5% | $5.2M-12.7% | $5.9M-8.5% | $4.9M-36.9% | $6.2M-29.9% | $5.9M-42.1% | $6.4M-44.3% |
| Cash & Equivalents | $1.3M-45.5% | $1.3M-56.3% | $2.5M+7.2% | $3.1M+8.3% | $2.4M-42.5% | $3.1M-42.5% | $2.4M-66.8% | $2.8M-64.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.7M+14.6% | $1.6M-0.6% | $1.5M-14.8% | $1.5M-24.2% | $1.5M-37.3% | $1.7M-22.3% | $1.8M-2.8% | $1.9M+3.5% |
| Accounts Receivable | $785K+7.4% | $941K-25.8% | $947K-28.6% | $1.2M-22.3% | $731K-22.8% | $1.3M+12.2% | $1.3M+24.3% | $1.6M+8.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.1M+124.4% | $1.6M-15.3% | $1.6M-26.0% | $1.7M-32.7% | $1.8M-30.9% | $1.8M-27.3% | $2.2M-11.8% | $2.5M+3.0% |
| Current Liabilities | $2.5M+42.6% | $1.6M-5.3% | $1.6M-14.8% | $1.7M-21.3% | $1.7M-21.1% | $1.6M-17.2% | $1.9M+3.0% | $2.2M+23.2% |
| Non-Current Liabilities | $1.6M+1548.0% | $0-100.0% | $0-100.0% | $6K-98.4% | $100K-78.2% | $193K-64.5% | $284K-54.6% | $373K-47.1% |
| Total Equity | $2.6M-35.9% | $3.3M-40.1% | $4.4M-13.3% | $5.2M-3.6% | $4.1M-37.7% | $5.5M-29.1% | $5.1M-45.5% | $5.3M-50.4% |
| Retained Earnings | -$56.9M-7.1% | -$55.8M-8.1% | -$54.5M-8.0% | -$53.2M-7.4% | -$53.2M-10.3% | -$51.6M-10.4% | -$50.5M-12.5% | -$49.5M-14.2% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$912K-37.8% | -$1.3M-19.6% | -$991K-25.3% | -$268K+80.1% | -$662K+36.6% | -$1.0M+42.0% | -$791K+6.1% | -$1.3M+19.7% |
| Depreciation & Amortization | $17K-26.1% | $20K-4.8% | $20K-9.1% | $20K-4.8% | $23K+4.5% | $21K+5.0% | $22K | $21K0.0% |
| Stock-Based Compensation | N/A | $58K-36.3% | $72K-53.5% | $133K+72.7% | N/A | $91K-73.2% | $155K+27.0% | $77K-54.7% |
| Investing Cash Flow | $18K | N/A | N/A | N/A | $0+100.0% | -$4K+75.0% | N/A | N/A |
| Financing Cash Flow | $871K+17520.0% | $61K-96.5% | $482K | $920K | -$5K | $1.7M | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -7.9%+25.1pp | -4.5%-6.2pp | 4.2%-22.5pp | 30.7%+14.7pp | -33.0%-35.0pp | 1.7%+16.3pp | 26.7%+6.0pp | 16.0%-8.1pp |
| Operating Margin | -174.8% | -131.5% | -113.5% | -81.0%-5.3pp | -209.1% | -108.1% | -60.7% | -75.7%-3.8pp |
| Net Margin | -130.7% | -132.9% | -109.1% | 0.1%+73.0pp | -206.1% | -103.9% | -58.1%+38.1pp | -72.8%-6.7pp |
| Return on Equity | -43.5%-5.9pp | -39.6%-18.5pp | -29.8%-11.2pp | 0.0%+24.7pp | -37.6%-16.1pp | -21.0%+3.5pp | -18.6%-2.5pp | -24.6%-14.1pp |
| Return on Assets | -16.9%+9.0pp | -26.9%-11.1pp | -21.9%-8.8pp | 0.0%+16.8pp | -26.0%-10.6pp | -15.8%+2.8pp | -13.1%-0.3pp | -16.7%-8.2pp |
| Current Ratio | 1.62-1.2x | 2.64-1.1x | 3.25+0.1x | 3.48+0.5x | 2.80-0.7x | 3.76-0.7x | 3.17-2.5x | 3.00-3.6x |
| Debt-to-Equity | 1.57+1.1x | 0.47+0.1x | 0.36-0.1x | 0.33-0.1x | 0.450.0x | 0.330.0x | 0.42+0.2x | 0.47+0.2x |
| Asset Turnover | 0.130.0x | 0.20+0.1x | 0.200.0x | 0.200.0x | 0.130.0x | 0.15+0.1x | 0.22+0.1x | 0.23+0.1x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIOMERICA INC BMRA | FY2026 | $4.5M | -$3.8M | -84.8% | $8.4M | 44/100 |
| HeartSciences Inc. HSCS | FY2026 | $4K | -$9.1M | N/A | $15.4M | — |
| PAVmed Inc. PAVM | FY2025 | $71K | -$3.8M | N/A | $22.3M | — |
| ReShape Lifesciences, Inc. RSLS | FY2025 | $320K | -$10.3M | N/A | $7.6M | — |
| Lifeward Ltd. LFWD | FY2025 | $22.0M | -$19.9M | -90.3% | $18.4M | 47/100 |
| STRATA SKIN SCIENCES INC SSKN | FY2025 | $30.7M | -$6.3M | -20.4% | $1.1M | — |
Where BIOMERICA INC Ranks
Frequently Asked Questions
What is BIOMERICA INC's annual revenue?
BIOMERICA INC (BMRA) reported $4.5M in total revenue for fiscal year 2026. This represents a -16.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BIOMERICA INC's revenue growing?
BIOMERICA INC (BMRA) revenue declined by 16.2% year-over-year, from $5.3M to $4.5M in fiscal year 2026.
Is BIOMERICA INC profitable?
No, BIOMERICA INC (BMRA) reported a net income of -$3.8M in fiscal year 2026, with a net profit margin of -84.8%.
What is BIOMERICA INC's EBITDA?
BIOMERICA INC (BMRA) had EBITDA of -$5.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is BIOMERICA INC's gross margin?
BIOMERICA INC (BMRA) had a gross margin of 8.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is BIOMERICA INC's net profit margin?
BIOMERICA INC (BMRA) had a net profit margin of -84.8% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is BIOMERICA INC's return on equity (ROE)?
BIOMERICA INC (BMRA) has a return on equity of -143.5% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is BIOMERICA INC's operating cash flow?
BIOMERICA INC (BMRA) recorded an outflow of $3.4M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are BIOMERICA INC's total assets?
BIOMERICA INC (BMRA) had $6.8M in total assets as of fiscal year 2026, including both current and long-term assets.
How much does BIOMERICA INC spend on research and development?
BIOMERICA INC (BMRA) invested $788K in research and development during fiscal year 2026.
What is BIOMERICA INC's current ratio?
BIOMERICA INC (BMRA) had a current ratio of 1.62 as of fiscal year 2026, which is generally considered healthy.
What is BIOMERICA INC's debt-to-equity ratio?
BIOMERICA INC (BMRA) had a debt-to-equity ratio of 1.57 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BIOMERICA INC's return on assets (ROA)?
BIOMERICA INC (BMRA) had a return on assets of -55.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is BIOMERICA INC's P/E ratio?
BIOMERICA INC (BMRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $8.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BIOMERICA INC's price-to-sales ratio?
BIOMERICA INC (BMRA) trades at 1.9x sales, its market capitalization divided by revenue of $4.5M revenue, FY2026. The market capitalization is $8.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BIOMERICA INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, BIOMERICA INC (BMRA) held $1.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BIOMERICA INC's Altman Z-Score?
BIOMERICA INC (BMRA) has an Altman Z-Score of -12.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BIOMERICA INC's Piotroski F-Score?
BIOMERICA INC (BMRA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BIOMERICA INC's earnings high quality?
BIOMERICA INC (BMRA) reported a net loss of $3.8M while operations used $3.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is BIOMERICA INC?
BIOMERICA INC (BMRA) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.